SMN2 copy number sets SMA severity across the Type 1–4 spectrum — and newborn screening has split the disease into pre-symptomatic and symptomatic populations with different treatment logic.
Spinal muscular atrophy is an autosomal-recessive motor-neuron disease caused by biallelic loss or mutation of SMN1, present in roughly 98% of cases. Severity is graded by the number of copies of the paralogous SMN2 gene, which produces a small amount of functional SMN protein: more SMN2 copies generally means a milder phenotype. US prevalence is estimated at 8,000–10,000 patients, with an incidence near 1 in 10,000 live births. The clinical spectrum runs from Type 1 (onset before six months, no independent sitting untreated) through Types 2 and 3 to the mildest Type 4 adult-onset form.
Two features define the modern landscape. First, natural history is severe at the Type 1 end: untreated, median survival is about 13.6 months, driven by rapid anterior-horn-cell loss in the first months of life, the window in which treatment matters most. Second, newborn screening has transformed detection: SMA was added to the federal Recommended Uniform Screening Panel in 2018, and all 50 states screen as of 2023, identifying roughly 300 infants a year before symptoms emerge. This creates two distinct populations (pre-symptomatic NBS-identified infants and older symptomatic patients) that call for different treatment strategies and drive different commercial segmentation.
SMA type spectrum — SMN2 copy number, onset, and clinical course
| Type | Typical SMN2 Copies | Onset | Share of Diagnoses | Defining Motor Feature | Untreated Course |
|---|---|---|---|---|---|
| Type 1 (Werdnig-Hoffmann) | 1–2 | <6 months | ~60% | Never sit unsupported | Median survival ~13.6 months without treatment |
| Type 2 | 3 | 6–18 months | ~27% | Sit, never walk | Survival to adulthood; respiratory and scoliosis burden |
| Type 3 (Kugelberg-Welander) | 3–4 | >18 months | ~13% | Walk, may lose ambulation | Near-normal lifespan; progressive weakness |
| Type 4 | 4+ | Adulthood | <5% | Mild proximal weakness | Normal lifespan |
| Pre-symptomatic (NBS-identified) | 2–3 (screened) | Detected at birth | ~300/yr (cross-type) | Asymptomatic at treatment | Near-normal development if treated early |
Sources: Prior TW, Genetics in Medicine 2010 (PMID 20057317); Finkel RS et al., Neurology 2014 — Type 1 natural history (PMID 25080519); CureSMA and the federal Recommended Uniform Screening Panel (RUSP) for newborn-screening coverage. SMN2 copy-number-to-phenotype mapping is a general genotype-phenotype correlation, not deterministic.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • SMN1 deletion mechanism and SMN2 as the disease modifier • Type 1–4 phenotype by SMN2 copy number • Motor-milestone trajectory by type • How copy number and age gate therapy eligibility
Delivers
- • RUSP addition and 50-state screening timeline • ~300 pre-symptomatic diagnoses per year • Pre-symptomatic vs symptomatic outcome divergence • Downstream segmentation for gene therapy vs chronic therapy
Delivers
- • Type 1 survival and milestone data • Respiratory and motor decline by type • Burden in older Type 2/3 patients on chronic therapy • Emerging questions on long-term treated outcomes
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Biallelic loss of SMN1 causes roughly 98% of SMA cases; SMN2 copy number is the modifier gene that sets phenotype severity
- Why more SMN2 copies generally means a milder phenotype, and how copy number becomes the treatment-selection axis
- US prevalence of roughly 8,000–10,000 patients, with incidence near 1 in 10,000 live births
- Type 1 accounts for roughly 60% of diagnoses, Type 2 about 27%, Type 3 about 13%, and Type 4 under 5%
- Untreated Type 1 median survival is about 13.6 months, driven by rapid anterior-horn-cell loss in the first months of life
- Motor trajectory by type: Type 2 patients sit but never walk, Type 3 patients walk but may lose ambulation, Type 4 has near-normal lifespan
- SMA joined the federal RUSP in 2018; all 50 states screen as of 2023, identifying roughly 300 infants a year before symptoms emerge
- Pre-symptomatic NBS-identified infants achieve near-normal motor development when treated early, a distinct population from symptomatic patients
- Type 2 patients survive to adulthood but carry respiratory and scoliosis burden requiring chronic management
- Type 3 patients retain near-normal lifespan but face progressive weakness and possible loss of ambulation over time
- Pre-symptomatic treatment produces near-normal motor development, but older Type 2/3 patients on chronic therapy still carry respiratory and scoliosis burden
- Where long-term treated-outcome data remains thin, particularly durability of effect and lifetime trajectory in NBS-identified infants
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
SMA disease landscape is built from primary epidemiological sources, peer-reviewed clinical literature, and registry data. Epidemiological estimates are triangulated across multiple sources; all figures carry source citations.
Key sources: Prior TW, Genet Med 2010 (PMID 20057317) for SMA genetics and prevalence; Finkel RS et al., Neurology 2014 (PMID 25080519) for Type 1 natural history; the federal Recommended Uniform Screening Panel and CureSMA for newborn-screening coverage; and FDA Drugs@FDA for approved-therapy context.
- Prevalence and genetics verified against Prior TW, Genet Med 2010 (PMID 20057317)
- Type 1 untreated survival verified against Finkel RS et al., Neurology 2014 (PMID 25080519)
- Newborn-screening coverage (RUSP 2018; 50 states 2023) verified against CureSMA and the federal RUSP
- SMN2 copy-number-to-severity relationship characterised as a genotype-phenotype correlation, not deterministic
Frequently asked questions
Commission this assessment
AXLRx Spinal Muscular Atrophy Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the US SMA patient population. Custom assessment in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.